S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NYSEAMERICAN:PLX

Protalix Biotherapeutics Stock Forecast, Price & News

$3.60
-0.04 (-1.10 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.58
Now: $3.60
$3.66
50-Day Range N/A
52-Week Range
$1.70
Now: $3.60
$4.86
Volume31,250 shs
Average Volume175,368 shs
Market Capitalization$116.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.
Read More
Protalix Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PLX
Previous SymbolNYSEMKT:PLX
CUSIPN/A
Phone+972-4-9028100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees184
Market Cap$116.79 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$3.60
-0.04 (-1.10 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Protalix Biotherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protalix Biotherapeutics
.

When is Protalix Biotherapeutics' next earnings date?

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Protalix Biotherapeutics
.

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $10.97 million for the quarter, compared to the consensus estimate of $10.88 million. During the same quarter in the previous year, the company posted ($0.50) EPS.
View Protalix Biotherapeutics' earnings history
.

When did Protalix Biotherapeutics' stock split? How did Protalix Biotherapeutics' stock split work?

Protalix Biotherapeutics's stock reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PLX?

1 equities research analysts have issued 12 month price objectives for Protalix Biotherapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price.
View analysts' price targets for Protalix Biotherapeutics
.

Who are some of Protalix Biotherapeutics' key competitors?

What other stocks do shareholders of Protalix Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BIOLINERX LTD/S (BLRX), VBI Vaccines (VBIV), Verastem (VSTM), Sangamo Therapeutics (SGMO), Opko Health (OPK), Sorrento Therapeutics (SRNE) and Biopharmx (BPMX).

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the following people:
  • Mr. Moshe Manor, CEO, Pres & Director (Age 63)
  • Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
  • Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 55)
  • Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix Biotherapeutics' major shareholders?

Protalix Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Psagot Investment House Ltd. (1.45%), Phoenix Holdings Ltd. (0.58%), Bridgeway Capital Management Inc. (0.54%), Bank of Montreal Can (0.54%) and Jane Street Group LLC (0.44%).
View institutional ownership trends for Protalix Biotherapeutics
.

Which major investors are buying Protalix Biotherapeutics stock?

PLX stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Bank of Montreal Can, Jane Street Group LLC, Bridgeway Capital Management Inc., and Psagot Investment House Ltd..
View insider buying and selling activity for Protalix Biotherapeutics
.

How do I buy shares of Protalix Biotherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $3.60.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $116.79 million. Protalix Biotherapeutics employs 184 workers across the globe.

What is Protalix Biotherapeutics' official website?

The official website for Protalix Biotherapeutics is www.protalix.com.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.